Autopsy report · NCT04955938

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

“unable to accrue”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

University of Chicago

Sponsor type

University, hospital or other

Conditions

IDH Mutation; IDH1 Mutation; IDH2 Gene Mutation; Blood Cancer; Myeloproliferative Neoplasm

Interventions

Ivosidenib; Enasidenib; Fedratinib

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
  “failure to accrue” (91% match in meaning)
• PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
  “Insufficient accrual” (83% match in meaning)
• Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
  “Unable to meet accrual goals” (68% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (68% match in meaning)
• Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers
  “Difficulty accruing” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.